Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYE Symphony: MT-302 in Advanced Epithelial Tumors
NCT05969041Phase 1Recruiting
- Sponsor
- Myeloid Therapeutics
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT-302 in urothelial carcinoma (UC), Cervical Cancer (CC), ovarian epithelial cancer and 7 more, sponsored by Myeloid Therapeutics. Primary endpoints: Incidence of Adverse Events and Maximum Tolerated Dose. Started Aug 2023; status: recruiting.
02
Drugs
MT-302
03
Conditions
urothelial carcinoma (UC)Cervical Cancer (CC)ovarian epithelial cancertriple-negative breast cancer (TNBC)Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05969041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969041.